NASDAQ:AKBA Akebia Therapeutics - AKBA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.86 +0.19 (+28.49%) (As of 02/2/2023 11:53 AM ET) Add Compare Share Share Today's Range$0.73▼$0.9050-Day Range$0.25▼$0.7452-Week Range$0.24▼$2.93Volume4.03 million shsAverage Volume1.72 million shsMarket Capitalization$158.37 millionP/E RatioN/ADividend YieldN/APrice Target$1.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Akebia Therapeutics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside118.8% Upside$1.75 Price TargetShort InterestHealthy2.51% of Shares Sold ShortDividend StrengthN/ASustainability-1.17Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.59) to ($0.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.14 out of 5 starsMedical Sector439th out of 1,030 stocksPharmaceutical Preparations Industry219th out of 502 stocks 3.0 Analyst's Opinion Consensus RatingAkebia Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.75, Akebia Therapeutics has a forecasted upside of 118.8% from its current price of $0.80.Amount of Analyst CoverageAkebia Therapeutics has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.51% of the outstanding shares of Akebia Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akebia Therapeutics has recently decreased by 0.86%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAkebia Therapeutics does not currently pay a dividend.Dividend GrowthAkebia Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAkebia Therapeutics has received a 68.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Various other types of medication (V)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Akebia Therapeutics is -1.17. Previous Next 2.7 News and Social Media Coverage News SentimentAkebia Therapeutics has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Akebia Therapeutics this week, compared to 1 article on an average week.Search Interest16 people have searched for AKBA on MarketBeat in the last 30 days. This is an increase of 220% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akebia Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.92% of the stock of Akebia Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 28.13% of the stock of Akebia Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.59) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akebia Therapeutics is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akebia Therapeutics is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkebia Therapeutics has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Akebia Therapeutics (NASDAQ:AKBA) StockAkebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.Read More Receive AKBA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AKBA Stock News HeadlinesJanuary 28, 2023 | americanbankingnews.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Receives $1.75 Average Target Price from BrokeragesJanuary 5, 2023 | thestreet.comAkebia Therapeutics (AKBA) Stock Declines Following Pricing of Secondary OfferingFebruary 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 22, 2022 | markets.businessinsider.comAkebia Receives Interim Response From FDA To Appeal For VadadustatDecember 22, 2022 | finance.yahoo.comAkebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDANovember 22, 2022 | finance.yahoo.comAkebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare ConferenceNovember 9, 2022 | finance.yahoo.comAkebia Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsNovember 4, 2022 | markets.businessinsider.comH.C. Wainwright Keeps Their Hold Rating on Akebia Therapeutics (AKBA)February 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.November 3, 2022 | seekingalpha.comAkebia Therapeutics, Inc. (AKBA) Q3 2022 Earnings Call TranscriptNovember 3, 2022 | finance.yahoo.comAkebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business HighlightsNovember 3, 2022 | finance.yahoo.comAkebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue EstimatesNovember 2, 2022 | msn.comAkebia Therapeutics Earnings PreviewOctober 27, 2022 | finance.yahoo.comAkebia Therapeutics to Report Third Quarter Financial Results and Highlight Recent Company MilestonesOctober 21, 2022 | finance.yahoo.comAkebia Therapeutics Announces Poster Presentation at ASN Kidney Week 2022October 7, 2022 | seekingalpha.comAkebia Therapeutics: FDA Approval Failure, Terminated Partnerships, And Looming LOE - Too RiskySeptember 1, 2022 | finance.yahoo.comAkebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 16, 2022 | msn.comAkebia Therapeutics Return On Capital Employed InsightsAugust 6, 2022 | seekingalpha.comAkebia Therapeutics Inc. (AKBA) CEO John Butler on Q2 2022 Results - Earnings Call TranscriptAugust 5, 2022 | finance.yahoo.comAkebia's Anemia Drug Disappoints In Mid-Stage COVID-19 StudyAugust 5, 2022 | finance.yahoo.comAkebia Therapeutics (AKBA) Surpasses Q2 Earnings and Revenue EstimatesAugust 4, 2022 | finance.yahoo.comAkebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Study Evaluating Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Subjects with COVID-19 and Hypoxemia (VSTAT)August 4, 2022 | finance.yahoo.comAkebia Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business HighlightsJuly 26, 2022 | finance.yahoo.comAkebia Therapeutics to Report Second Quarter Financial ResultsJuly 3, 2022 | marketwatch.comThinking about buying stock in Akebia Therapeutics, Agile Therapeutics, Mullen Automotive, Evofem Biosciences, or Endo International?June 30, 2022 | seekingalpha.comAkebia regains rights to kidney disease therapy after termination of deals with OtsukaJune 30, 2022 | finance.yahoo.comAkebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with OtsukaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AKBA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AKBA Company Calendar Last Earnings11/04/2021Today2/02/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKBA CUSIPN/A CIK1517022 Webwww.akebia.com Phone(617) 871-2098Fax617-871-2099Employees426Year FoundedN/APrice Target and Rating Average Stock Price Forecast$1.75 High Stock Price Forecast$2.00 Low Stock Price Forecast$1.25 Forecasted Upside/Downside+103.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-282,840,000.00 Net Margins-52.42% Pretax Margin-52.42% Return on Equity-315.92% Return on Assets-27.97% Debt Debt-to-Equity RatioN/A Current Ratio1.26 Quick Ratio1.05 Sales & Book Value Annual Sales$213.58 million Price / Sales0.74 Cash FlowN/A Price / Cash FlowN/A Book Value$0.44 per share Price / Book1.96Miscellaneous Outstanding Shares183,960,000Free Float178,590,000Market Cap$158.37 million OptionableOptionable Beta0.91 Key ExecutivesJohn P. ButlerPresident, Chief Executive Officer & DirectorMichel DahanChief Operating Officer & Senior Vice PresidentDavid A. SpellmanTreasurer, Chief Financial & Accounting OfficerSteven K. BurkeChief Medical Officer & Senior Vice PresidentMichael RabinowitzVice President-ResearchKey CompetitorsWerewolf TherapeuticsNASDAQ:HOWLESSA PharmaNASDAQ:EPIXPieris PharmaceuticalsNASDAQ:PIRSMereo BioPharma GroupNASDAQ:MREOSesen BioNASDAQ:SESNView All CompetitorsInsiders & InstitutionsBlackRock Inc.Sold 53,070 shares on 11/15/2022Ownership: 2.330%Federated Hermes Inc.Sold 188,931 shares on 11/15/2022Ownership: 0.979%Public Employees Retirement System of OhioBought 183,979 shares on 11/15/2022Ownership: 0.100%Price T Rowe Associates Inc. MDBought 119,800 shares on 11/15/2022Ownership: 0.091%Citadel Advisors LLCBought 6,400 shares on 11/15/2022Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions AKBA Stock - Frequently Asked Questions Should I buy or sell Akebia Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 6 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AKBA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKBA, but not buy additional shares or sell existing shares. View AKBA analyst ratings or view top-rated stocks. What is Akebia Therapeutics' stock price forecast for 2023? 6 analysts have issued 12 month target prices for Akebia Therapeutics' stock. Their AKBA share price forecasts range from $1.25 to $2.00. On average, they expect the company's share price to reach $1.75 in the next twelve months. This suggests a possible upside of 161.2% from the stock's current price. View analysts price targets for AKBA or view top-rated stocks among Wall Street analysts. How have AKBA shares performed in 2023? Akebia Therapeutics' stock was trading at $0.5770 at the beginning of the year. Since then, AKBA shares have increased by 16.1% and is now trading at $0.67. View the best growth stocks for 2023 here. When is Akebia Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our AKBA earnings forecast. How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics, Inc. (NASDAQ:AKBA) issued its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.02. The biopharmaceutical company had revenue of $48.76 million for the quarter, compared to the consensus estimate of $50.09 million. Akebia Therapeutics had a negative trailing twelve-month return on equity of 315.92% and a negative net margin of 52.42%. During the same quarter last year, the company earned ($0.42) earnings per share. What is John Butler's approval rating as Akebia Therapeutics' CEO? 28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com. John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T). What is Akebia Therapeutics' stock symbol? Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA." Who are Akebia Therapeutics' major shareholders? Akebia Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David A Spellman, Dell Faulkingham, Jason Amello, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman, Steven C Gilman, Steven Keith Burke and Violetta Cotreau. View institutional ownership trends. How do I buy shares of Akebia Therapeutics? Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Akebia Therapeutics' stock price today? One share of AKBA stock can currently be purchased for approximately $0.67. How much money does Akebia Therapeutics make? Akebia Therapeutics (NASDAQ:AKBA) has a market capitalization of $123.25 million and generates $213.58 million in revenue each year. The biopharmaceutical company earns $-282,840,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. How many employees does Akebia Therapeutics have? The company employs 426 workers across the globe. How can I contact Akebia Therapeutics? Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The official website for the company is www.akebia.com. The biopharmaceutical company can be reached via phone at (617) 871-2098, via email at ir@akebia.com, or via fax at 617-871-2099. This page (NASDAQ:AKBA) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.